Display options
Cite
Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. Jundishapur J Microbiol. 2016;9(3):e16241doi: 10.5812/jjm.16241.
Moazen, B., Ebrahimi, E., & Nejatollahi, F. (2016). Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. Jundishapur journal of microbiology, 9(3), e16241. https://doi.org/10.5812/jjm.16241
Moazen, Bahareh, et al. "Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections." Jundishapur journal of microbiology vol. 9,3 (2016): e16241. doi: https://doi.org/10.5812/jjm.16241
Moazen B, Ebrahimi E, Nejatollahi F. Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections. Jundishapur J Microbiol. 2016 Mar 15;9(3):e16241. doi: 10.5812/jjm.16241. eCollection 2016 Mar. PMID: 27217918; PMCID: PMC4870390.
Copy Download .nbib Format: NLM
Share it on

Jundishapur J Microbiol. 2016 Mar 15;9(3):e16241. doi: 10.5812/jjm.16241. eCollection 2016 Mar.

Single Chain Antibodies Against gp55 of Human Cytomegalovirus (HCMV) for Prophylaxis and Treatment of HCMV Infections.

Jundishapur journal of microbiology

Bahareh Moazen, Elahe Ebrahimi, Foroogh Nejatollahi

Affiliations

  1. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  2. Department of Immunology, Recombinant Antibody Laboratory, Shiraz University of Medical Sciences, Shiraz, IR Iran.
  3. Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran; Department of Immunology, Recombinant Antibody Laboratory, Shiraz University of Medical Sciences, Shiraz, IR Iran.

PMID: 27217918 PMCID: PMC4870390 DOI: 10.5812/jjm.16241

Abstract

BACKGROUND: Immunotherapy is a promising prospective new treatment for cytomegalovirus (CMV) infections. Neutralizing effects have been reported using monoclonal antibodies. Recombinant single chain antibodies (scFvs) due to their advantages over monoclonal antibodies are potential alternatives and provide valuable clinical agents.

OBJECTIVES: The aim of this study was to select specific single chain antibodies against gp55 of CMV and to evaluate their neutralizing effects. In the present study, we selected specific single chain antibodies against glycoprotein 55 (gp55) of CMV for their use in treatment and diagnosis.

MATERIALS AND METHODS: Single chain antibodies specific against an epitope located in the C-terminal part of gp55 were selected from a phage antibody display library. After four rounds of panning, twenty clones were amplified by the polymerase chain reaction (PCR) and fingerprinted by MvaI restriction enzyme. The reactivities of the specific clones were tested by the enzyme-linked immunosorbent assay (ELISA) and the neutralizing effects were evaluated by the plaque reduction assay.

RESULTS: Fingerprinting of selected clones revealed three specific single chain antibodies (scFv1, scFv2 and scFv3) with frequencies 25%, 20 and 20%. The clones produced positive ELISA with the corresponding peptide. The percentages of plaque reduction for scFv1, scFv2 and scFv3 were 23.7, 68.8 and 11.6, respectively.

CONCLUSIONS: Gp55 of human CMV is considered as an important candidate for immunotherapy. In this study, we selected three specific clones against gp55. The scFvs reacted only with the corresponding peptide in a positive ELISA. The scFv2 with 68.8% neutralizing effect showed the potential to be considered for prophylaxis and treatment of CMV infections, especially in solid organ transplant recipients, for whom treatment of CMV is urgently needed. The scFv2 with neutralizing effect of 68.8%, has the potential to be considered for treatment of these patients. The specific scFv1 and scFv3 with lower neutralizing effects can be used for diagnostic purposes.

Keywords: CMV; Gp55; Neutralizing Effect; Single-Chain Antibodies

References

  1. Liver Transpl. 2012 Dec;18(12):1448-55 - PubMed
  2. Crit Care Med. 2008 Dec;36(12):3145-50 - PubMed
  3. J Virol. 2000 Feb;74(3):1383-92 - PubMed
  4. Can J Microbiol. 2011 Apr;57(4):273-7 - PubMed
  5. Nat Rev Nephrol. 2010 Dec;6(12):711-21 - PubMed
  6. Am J Health Syst Pharm. 2010 Sep 1;67(17):1417-25 - PubMed
  7. Tumour Biol. 2014 Aug;35(8):7887-95 - PubMed
  8. Gac Med Mex. 2011 Mar-Apr;147(2):159-62 - PubMed
  9. Biotechnol Adv. 2009 Jul-Aug;27(4):502-20 - PubMed
  10. Clin Vaccine Immunol. 2010 Nov;17(11):1708-17 - PubMed
  11. Am J Transplant. 2009 Nov;9(11):2453-8 - PubMed
  12. FEMS Immunol Med Microbiol. 2002 Nov 15;34(3):237-44 - PubMed
  13. Oncoimmunology. 2013 Jun 1;2(6):e24439 - PubMed
  14. Curr Opin Biotechnol. 2002 Dec;13(6):603-8 - PubMed
  15. Infect Disord Drug Targets. 2011 Oct;11(5):432-6 - PubMed
  16. New Microbiol. 2011 Jul;34(3):229-54 - PubMed
  17. Vaccine. 2007 Dec 21;26(1):41-6 - PubMed
  18. AIDS. 2009 Oct 23;23(16):2173-81 - PubMed
  19. J Immunol Methods. 2011 Mar 7;366(1-2):60-8 - PubMed
  20. Antiviral Res. 2004 Nov;64(2):103-11 - PubMed
  21. J Immunother. 2006 Mar-Apr;29(2):107-21 - PubMed
  22. Asian Pac J Allergy Immunol. 2008 Mar;26(1):23-35 - PubMed
  23. Braz J Med Biol Res. 2012 Jul;45(7):583-90 - PubMed
  24. Pediatr Infect Dis J. 2002 Feb;21(2):133-8 - PubMed
  25. Transpl Infect Dis. 2011 Jun;13(3):318-23 - PubMed
  26. Inflamm Allergy Drug Targets. 2010 Sep;9(4):286-99 - PubMed
  27. PLoS One. 2011;6(12):e27756 - PubMed
  28. Vet Microbiol. 2011 Jan 10;147(1-2):162-9 - PubMed
  29. Nucleic Acids Res. 2002 Mar 1;30(5):e18 - PubMed
  30. J Virol. 2009 Dec;83(24):12854-70 - PubMed
  31. Hepatobiliary Pancreat Dis Int. 2006 May;5(2):237-41 - PubMed

Publication Types